Agios Pharmaceuticals (AGIO) Receivables (2014 - 2026)

Agios Pharmaceuticals (AGIO) has 12 years of Receivables data on file, last reported at $28.3 million in Q2 2026.

• Quarterly Receivables rose 184.0% year-over-year to $28.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $28.3 million (up 184.0% YoY) and the FY2025 annual result came in at $10.6 million, up 28.71% from the prior year.
• Receivables eased to $28.3 million in Q2 2026, from $32.3 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $32.3 million in Q1 2026 to a low of $2.4 million in Q3 2023.
• A 5-year average of $9.1 million and a median of $6.5 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2023 — Receivables slumped 57.94% — and 2026, when it surged 382.42%.
• Tracing AGIO's Receivables over 5 years: stood at $4.4 million in 2022, then increased by 27.38% to $5.6 million in 2023, then jumped by 46.23% to $8.2 million in 2024, then grew by 28.71% to $10.6 million in 2025, then soared by 167.75% to $28.3 million in 2026.
• The last three Receivables figures came in at $28.3 million (Q2 2026), $32.3 million (Q1 2026), and $10.6 million (Q4 2025), per Business Quant data.